LENSAR, Inc. Common Stock (LNSR) — 分析摘要
LENSAR, Inc. Common Stock(LNSR)的市值为68.78百万美元,最近一年的营收同比增长了+12.4%。净利润率为-66.4%。当前市盈率为2.3倍。
核心要点
- 营收同比变化+12.4%
- 净利润率-66.4%
- 市盈率2.3倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,LNSR的营收增长为+12.4%,市盈率为2.3倍。
LENSAR, Inc. Common Stock (LNSR)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -32.4% — 经营亏损显著
最新报表显示自由现金流为负。
经营现金流为负,但净利润仍为正。
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
150
总部
ORLANDO, FL
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。